Amgen's Otezla notches win in genital psoriasis, snagging possible edge against forthcoming BMS rival

With a potential Bristol Myers rival looming on the horizon, Amgen's inflammatory disease med Otezla is hustling to cement its position in psoriasis. Now, the drug has notched a win in a trial for a highly stigmatized disease that can affect more than half of psoriasis patients.